Literature DB >> 1709376

Autoantibodies to the presumptive cytoplasmic domain of platelet glycoprotein IIIa in patients with chronic immune thrombocytopenic purpura.

K Fujisawa1, T E O'Toole, P Tani, J C Loftus, E F Plow, M H Ginsberg, R McMillan.   

Abstract

Chronic immune thrombocytopenic purpura (ITP) is an autoimmune disorder due to autoantibodies against platelets that result in their destruction. In some patients, these autoantibodies bind to platelet glycoprotein (GP) IIIa. With the aim of better defining the antigenic epitopes, plasma from 13 selected patients with chronic ITP known to have anti-GPIIb/IIIa autoantibodies was tested for reactivity with nine synthetic peptides corresponding to different regions of the GP IIIa molecule. Of these plasmas, five bound significantly (P less than .001) with either peptide 8 (amino acids 721-744) or peptide 9 (amino acids 742-762), which together form most of the carboxyterminal region presumed to be the cytoplasmic domain. Three of these positive plasmas, were tested further. In two of these positive plasmas, the anti-peptide antibodies represented greater than 80% of the detectable circulating autoantibody. To further evaluate the importance of the carboxyterminal region as an antigenic site, the chronic ITP plasmas were tested against Chinese hamster ovary cells transfected with GPIIb and either whole GPIIIa or GPIIIa lacking amino acids 728 to 762. Ten of the 13 plasmas required the presence of this region for significant autoantibody binding. We conclude that the carboxyterminal region is an important area for stimulating antiplatelet autoantibody formation in some patients with chronic ITP. It is not known whether these autoantibodies to the presumed cytoplasmic domain play an important role in the pathogenesis of the disease or occur as a secondary phenomenon during the course of platelet destruction.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1709376

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Autoantigenic epitopes on platelet glycoproteins.

Authors:  Yoshiaki Tomiyama; Satoru Kosugi
Journal:  Int J Hematol       Date:  2005-02       Impact factor: 2.490

2.  GPIIIa-(49-66) is a major pathophysiologically relevant antigenic determinant for anti-platelet GPIIIa of HIV-1-related immunologic thrombocytopenia.

Authors:  M A Nardi; L X Liu; S Karpatkin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

3.  Comparative study of IgG binding to megakaryocytes in immune and myelodysplastic thrombocytopenic patients.

Authors:  Doaa I Elzaeem; Esmat A El Sharkawi; Eman M Zaki; Ayman G Ghobrial; Aliaa S Abd El-Fatah; Waleed M Abd El-Hamed
Journal:  Ann Hematol       Date:  2021-05-13       Impact factor: 3.673

4.  Establishment of a cell line panel for the detection of antibodies against human platelet antigen 4b.

Authors:  Tomoya Hayashi; Etsuko Amakishi; Masayasu Inoue; Fumiya Hirayama
Journal:  Int J Hematol       Date:  2011-02-01       Impact factor: 2.490

5.  Antiplatelet glycoprotein autoantibodies in patients with autoimmune diseases with and without thrombocytopenia.

Authors:  I Cordiano; F Salvan; M L Randi; M A Ruffatti; A Steffan; A Girolami; F Fabris
Journal:  J Clin Immunol       Date:  1996-11       Impact factor: 8.317

6.  Laboratory investigation of immune thrombocytopenia.

Authors:  M Warner; J G Kelton
Journal:  J Clin Pathol       Date:  1997-01       Impact factor: 3.411

7.  Novel Mouse Model for Studying Hemostatic Function of Human Platelets.

Authors:  David S Paul; Wolfgang Bergmeier
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-06-04       Impact factor: 8.311

8.  Detection of anti-human platelet antibodies against integrin α2β1 using cell lines.

Authors:  Tomoya Hayashi; Etsuko Amakishi; Nobuki Matsuyama; Kazuta Yasui; Rika Ann Furuta; Yuji Hori; Shigenori Tanaka; Yasuo Fukumori; Fumiya Hirayama
Journal:  Blood Transfus       Date:  2012-11-22       Impact factor: 3.443

Review 9.  Pathogenesis and Therapeutic Mechanisms in  Immune Thrombocytopenia (ITP).

Authors:  Anne Zufferey; Rick Kapur; John W Semple
Journal:  J Clin Med       Date:  2017-02-09       Impact factor: 4.241

Review 10.  Emerging Concepts in Immune Thrombocytopenia.

Authors:  Maurice Swinkels; Maaike Rijkers; Jan Voorberg; Gestur Vidarsson; Frank W G Leebeek; A J Gerard Jansen
Journal:  Front Immunol       Date:  2018-04-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.